Medical management of high-grade astrocytoma: Current and emerging therapies

Derek R. Johnson, Evanthia Galanis

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

High-grade astrocytomas are aggressive and incurable primary brain tumors. Radiation therapy with concurrent and adjuvant temozolomide chemotherapy is the standard-of-care treatment for newly diagnosed glioblastoma, while the role of chemotherapy in the initial treatment of anaplastic astrocytoma is evolving. Currently available medical options at tumor progression include further cytotoxic therapy and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab. Investigational treatments including numerous molecularly targeted agents and immunotherapeutic approaches are currently being evaluated. Significant future progress will require better understanding and exploitation of the molecular heterogeneity within high-grade astrocytoma, as well as innovative trial designs to evaluate efficiently targeted therapies in the subsets of patients in which they are most likely to be effective.

Original languageEnglish (US)
Pages (from-to)511-522
Number of pages12
JournalSeminars in oncology
Volume41
Issue number4
DOIs
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Medical management of high-grade astrocytoma: Current and emerging therapies'. Together they form a unique fingerprint.

  • Cite this